Matt S Anderson
Overview
Explore the profile of Matt S Anderson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Anderson M, Gilmartin J, Fan L, Yee K, Kraft W, Triantafyllou I, et al.
Antivir Ther
. 2019 Aug;
24(6):443-450.
PMID: 31433304
Background: Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor available as a single tablet and a three-drug combination with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) to treat HIV-1...
12.
Khalilieh S, Yee K, Sanchez R, Fan L, Anderson M, Sura M, et al.
Antimicrob Agents Chemother
. 2019 Feb;
63(5).
PMID: 30783000
Identifying and understanding potential drug-drug interactions (DDIs) are vital for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This article discusses DDIs between doravirine, a nonnucleoside reverse transcriptase...
13.
Sanchez R, Fillgrove K, Yee K, Liang Y, Lu B, Tatavarti A, et al.
Xenobiotica
. 2018 Mar;
49(4):422-432.
PMID: 29557716
Absorption, distribution, metabolism and elimination of doravirine (MK-1439), a novel non-nucleoside reverse transcriptase inhibitor, were investigated. Two clinical trials were conducted in healthy subjects: an oral single dose [C]doravirine (350 ...
14.
Anderson M, Kosoglou T, Statkevich P, Li J, Rotonda J, Meehan A, et al.
Clin Pharmacol Drug Dev
. 2017 Apr;
7(2):143-150.
PMID: 28403576
Vorapaxar is a first-in-class antagonist of the protease-activated receptor-1, the primary thrombin receptor on human platelets, which mediates the downstream effects of thrombin in hemostasis and thrombosis. Prasugrel is a...
15.
Yee K, Khalilieh S, Sanchez R, Liu R, Anderson M, Manthos H, et al.
Clin Drug Investig
. 2017 Mar;
37(7):659-667.
PMID: 28353169
Background And Objective: Doravirine is a novel, next-generation, non-nucleoside reverse transcriptase inhibitor in development for the treatment of human immunodeficiency virus-1 infection in combination with other antiretrovirals. Doravirine is a...
16.
Anderson M, Khalilieh S, Yee K, Liu R, Fan L, Rizk M, et al.
Clin Pharmacokinet
. 2017 Feb;
56(6):679-681.
PMID: 28185217
No abstract available.
17.
Anderson M, Khalilieh S, Yee K, Liu R, Fan L, Rizk M, et al.
Clin Pharmacokinet
. 2016 Oct;
56(6):661-669.
PMID: 27699622
Introduction: Doravirine, a non-nucleoside reverse-transcriptase inhibitor in development for the treatment of patients with human immunodeficiency virus-1 infection, has potential to be used concomitantly in antiretroviral therapy with dolutegravir, an...
18.
Schurmann D, Sobotha C, Gilmartin J, Robberechts M, De Lepeleire I, Yee K, et al.
AIDS
. 2015 Sep;
30(1):57-63.
PMID: 26372481
Objective: To assess the antiviral activity, pharmacokinetics, and safety of doravirine in nonnucleoside reverse transcriptase inhibitor-naïve, HIV-infected men. Design: Double-blind, randomized, two-panel, dose-escalation study. Methods: In two sequential panels, 18...
19.
Anderson M, Gilmartin J, Cilissen C, De Lepeleire I, van Bortel L, Dockendorf M, et al.
Antivir Ther
. 2014 Dec;
20(4):397-405.
PMID: 25470746
Background: Doravirine is a novel non-nucleoside inhibitor of HIV-1 reverse transcriptase with potent activity against wild-type virus (95% inhibitory concentration 19 nM, 50% human serum). Doravirine has low potential to...
20.
Thompson C, Ali A, Quraishi N, Lu Z, Hammond M, Sinclair P, et al.
ACS Med Chem Lett
. 2014 Jun;
2(6):424-7.
PMID: 24900324
Recently, there has been a strong interest in the ability to increase levels of high density lipoprotein-cholesterol (HDL-C). This interest stems from the hypothesis that such an elevation in HDL-C...